Tumor protein p53-derived peptide–Major Histocompatibility Complex class II complex (p53-MHC II complex)

The Tumor protein p53-derived peptide–Major Histocompatibility Complex class II complex is a molecular assembly formed on the surface of antigen-presenting cells, such as dendritic cells, to initiate adaptive immune responses [PubMed: 10880450]. It consists of a peptide fragment derived from the p53 tumor suppressor protein—which is frequently mutated or overexpressed in various malignancies—bound within the peptide-binding groove of a Major Histocompatibility Complex (MHC) class II molecule [UniProt: P04637]. This complex is specifically recognized by the T-cell receptors (TCRs) of CD4+ T helper cells, which are essential for orchestrating a comprehensive anti-tumor response by providing help to CD8+ cytotoxic T cells and B cells [Nature Reviews Cancer, 2014]. In the context of cancer immunotherapy, this complex is a primary target for dendritic cell vaccines, such as INGN 225, which are designed to enhance the presentation of p53 antigens and overcome immunological tolerance to tumor cells [PubMed: 18483239]. By stimulating p53-specific T-cell immunity, these therapies aim to achieve targeted destruction of tumor cells while minimizing damage to normal tissues where p53 expression is typically low.

Other names

p53-HLA class II complexp53-MHC IIp53-HLA-DR complexp53 peptide-MHC class II complexp53-derived peptide–MHC class II complex on dendritic cells

Stimulation of p53-specific CD4+ T helper cells to enhance anti-tumor immunity through the presentation of p53-derived epitopes on MHC class II molecules [PubMed: 10880450].